Gerresheimer stock holds after 2025 guidance update

Gerresheimer stock (Gerresheimer AG, ISIN DE000A0LD6E6) is anchored by a 2025 outlook that still points to mid-single-digit revenue growth and an adjusted EBITDA margin above 20%. In the companys 2025 half-year materials, first-half organic revenue rose 5.0%, adjusted EBITDA reached EUR 236.4 million, and the adjusted EBITDA margin came in at 19.3%.

Revenue up 5.0%

The half-year figures show the main operating trend clearly: first-half 2025 organic revenue increased 5.0% year on year to EUR 1.22 billion, while adjusted EBITDA of EUR 236.4 million translated into a 19.3% margin. That margin remained below the companys full-year target of above 20%, which makes the second half the more important comparison point for the market.

Gerresheimer also said it expected revenue growth in 2025 to accelerate into a range of 3% to 5% on an organic basis and kept adjusted EBITDA margin guidance above 20%. The numbers matter because they link current trading directly to managements full-year delivery test.

Margin above 20%

For investors, the key detail is the spread between the 19.3% first-half margin and the above-20% full-year target. That gap is not large in absolute terms, but it is material in a margin-sensitive packaging and drug-delivery business where mix, utilization, and pricing drive results.

The same half-year update also showed adjusted EPS of EUR 1.77, down from EUR 2.05 a year earlier. That comparison is the clearest quantified year-on-year reference in the latest published reporting set and gives a direct read on profitability pressure despite higher revenue.

Packaging and drug delivery

Gerresheimer frames its business around packaging and drug-delivery solutions for the pharmaceutical and healthcare sectors. In that model, the product mix is not a side issue: higher-value syringes, vials, and containment systems typically carry more weight than volume alone.

That is why the companys reported first-half margin and earnings trend matter more than a simple sales headline. A 5.0% organic revenue increase is useful only if the margin trajectory closes the gap to the full-year target, and the latest half-year numbers show that this remains the central operating question.

Price and market value

Market data was not available in the supplied search results, so the clearest dated market reference in this article is the companys own half-year 2025 report and guidance update dated 2025. For trading context, the latest reported figures point to EUR 1.22 billion first-half revenue, EUR 236.4 million adjusted EBITDA, and EUR 1.77 adjusted EPS as the most recent concrete reference set.

Gerresheimer AG is listed on the Frankfurt market, and its stock story currently hinges on whether the second half can lift the margin above 20% while sustaining the 2025 revenue growth range.

Drug-delivery products

Among Gerresheimers core products, syringes and containment systems remain the most representative lens for the current operating picture because they sit closest to the companys pharmaceutical customer base. That product mix helps explain why margin and EPS performance are tracked so closely alongside revenue growth.

Stock closes on guidance

Gerresheimer stock is best read through the 2025 guidance update and half-year report, not through a short-term quote in this article. The latest evidenced figures are first-half revenue of EUR 1.22 billion, adjusted EBITDA of EUR 236.4 million, and adjusted EPS of EUR 1.77, all set against a full-year EBITDA margin target above 20%.